605 related articles for article (PubMed ID: 26103617)
41. Targeting specific cells in the brain with nanomedicines for CNS therapies.
Zhang F; Lin YA; Kannan S; Kannan RM
J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
[TBL] [Abstract][Full Text] [Related]
42. Nanotechnologies: a strategy to overcome blood-brain barrier.
De Rosa G; Salzano G; Caraglia M; Abbruzzese A
Curr Drug Metab; 2012 Jan; 13(1):61-9. PubMed ID: 22292810
[TBL] [Abstract][Full Text] [Related]
43. [Neurological disorders and the blood-brain barrier. Strategies and limitations for drug delivery to the brain].
Domínguez A; Álvarez A; Suárez-Merino B; Goñi-de-Cerio F
Rev Neurol; 2014 Mar; 58(5):213-24. PubMed ID: 24570360
[TBL] [Abstract][Full Text] [Related]
44. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma.
Saesoo S; Sathornsumetee S; Anekwiang P; Treetidnipa C; Thuwajit P; Bunthot S; Maneeprakorn W; Maurizi L; Hofmann H; Rungsardthong RU; Saengkrit N
Colloids Surf B Biointerfaces; 2018 Jan; 161():497-507. PubMed ID: 29128836
[TBL] [Abstract][Full Text] [Related]
45. The blood-brain barrier: clinical implications for drug delivery to the brain.
De Boer AG; Breimer DD
J R Coll Physicians Lond; 1994; 28(6):502-6. PubMed ID: 7884704
[TBL] [Abstract][Full Text] [Related]
46. Current approaches to enhance CNS delivery of drugs across the brain barriers.
Lu CT; Zhao YZ; Wong HL; Cai J; Peng L; Tian XQ
Int J Nanomedicine; 2014; 9():2241-57. PubMed ID: 24872687
[TBL] [Abstract][Full Text] [Related]
47. Strategy for effective brain drug delivery.
Alam MI; Beg S; Samad A; Baboota S; Kohli K; Ali J; Ahuja A; Akbar M
Eur J Pharm Sci; 2010 Aug; 40(5):385-403. PubMed ID: 20497904
[TBL] [Abstract][Full Text] [Related]
48. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
[TBL] [Abstract][Full Text] [Related]
49. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
[TBL] [Abstract][Full Text] [Related]
50. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
Juillerat-Jeanneret L
Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
[TBL] [Abstract][Full Text] [Related]
51. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
Sa P; Singh P; Dilnawaz F; Sahoo SK
Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
[TBL] [Abstract][Full Text] [Related]
52. Theranostical application of nanomedicine for treating central nervous system disorders.
Ran W; Xue X
Sci China Life Sci; 2018 Apr; 61(4):392-399. PubMed ID: 29675554
[TBL] [Abstract][Full Text] [Related]
53. Intranasal drug delivery to the central nervous system: present status and future outlook.
Tayebati SK; Nwankwo IE; Amenta F
Curr Pharm Des; 2013; 19(3):510-26. PubMed ID: 23116337
[TBL] [Abstract][Full Text] [Related]
54. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
Peluffo H; Unzueta U; Negro-Demontel ML; Xu Z; Váquez E; Ferrer-Miralles N; Villaverde A
Biotechnol Adv; 2015; 33(2):277-87. PubMed ID: 25698504
[TBL] [Abstract][Full Text] [Related]
55. Brain drug delivery systems.
Jiang X
Pharm Res; 2013 Oct; 30(10):2427-8. PubMed ID: 23921487
[No Abstract] [Full Text] [Related]
56. [Breaking down barriers--about the art of escorting drugs into the brain].
Kahl U
Lakartidningen; 2003 Jan; 100(3):136-7. PubMed ID: 12596480
[No Abstract] [Full Text] [Related]
57. Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.
Patel MM; Patel BM
CNS Drugs; 2017 Feb; 31(2):109-133. PubMed ID: 28101766
[TBL] [Abstract][Full Text] [Related]
58. Implantable and transdermal polymeric drug delivery technologies for the treatment of central nervous system disorders.
Govender T; Choonara YE; Kumar P; Bijukumar D; du Toit LC; Modi G; Naidoo D; Pillay V
Pharm Dev Technol; 2017 Jun; 22(4):476-486. PubMed ID: 27268737
[TBL] [Abstract][Full Text] [Related]
59. Polymeric nanoparticles - targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities.
Rollerova E; Scsukova S; Jurcovicova J; Mlynarcikova A; Szabova E; Kovriznych J; Zeljenkova D
Endocr Regul; 2011 Jan; 45(1):49-60. PubMed ID: 21314211
[TBL] [Abstract][Full Text] [Related]
60. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier.
Sharma G; Sharma AR; Lee SS; Bhattacharya M; Nam JS; Chakraborty C
Int J Pharm; 2019 Mar; 559():360-372. PubMed ID: 30721725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
